- Home
- ACRE vs TERN Comparison
ACRE vs TERN Comparison
Compare ACRE & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- TERN
- Stock Information
- Founded
- ACRE 2011
- TERN 2017
- Country
- ACRE United States
- TERN United States
- Employees
- ACRE N/A
- TERN N/A
- Industry
- ACRE Real Estate Investment Trusts
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- TERN Health Care
- Exchange
- ACRE Nasdaq
- TERN Nasdaq
- Market Cap
- ACRE 259.5M
- TERN 310.8M
- IPO Year
- ACRE 2012
- TERN 2021
- Fundamental
- Price
- ACRE $4.83
- TERN $3.04
- Analyst Decision
- ACRE Hold
- TERN Buy
- Analyst Count
- ACRE 7
- TERN 5
- Target Price
- ACRE $5.19
- TERN $18.38
- AVG Volume (30 Days)
- ACRE 599.3K
- TERN 1.0M
- Earning Date
- ACRE 05-07-2025
- TERN 05-08-2025
- Dividend Yield
- ACRE 12.29%
- TERN N/A
- EPS Growth
- ACRE N/A
- TERN N/A
- EPS
- ACRE N/A
- TERN N/A
- Revenue
- ACRE $67,129,000.00
- TERN N/A
- Revenue This Year
- ACRE N/A
- TERN N/A
- Revenue Next Year
- ACRE $7.37
- TERN N/A
- P/E Ratio
- ACRE N/A
- TERN N/A
- Revenue Growth
- ACRE 83.51
- TERN N/A
- 52 Week Low
- ACRE $3.35
- TERN $1.87
- 52 Week High
- ACRE $7.99
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ACRE 70.34
- TERN 51.89
- Support Level
- ACRE $4.03
- TERN $2.93
- Resistance Level
- ACRE $4.00
- TERN $3.62
- Average True Range (ATR)
- ACRE 0.18
- TERN 0.25
- MACD
- ACRE 0.15
- TERN 0.03
- Stochastic Oscillator
- ACRE 95.24
- TERN 39.27
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.